ImmunoCellular Therapeutics Ltd. on Wednesday announced that the board of directors has appointed Dr. Anthony Gringeri as its new chief executive, following the resignation of former chief executive Andrew Gengos. Gengos’ resignation was announced at the same time. The Calabasas cancer treatment company declined to comment on the reason for his resignation, but said he will continue as a member of the board. Gringeri has served as ImmunoCellular’s senior vice president of strategic resources since 2013 and has been instrumental in moving its products through clinical trials and regulatory hurdles. He led the efforts behind cancer drug ICT-107’s phase 3 registration trial in newly diagnosed glioblastoma brain tumors as well as the ICT-121 phase 1 trial in recurrent glioblastoma. As chief executive, Gringeri will also join the board, the company said. “Tony (Gringeri) is an accomplished and driven biopharmaceutical executive and team leader with extensive clinical development experience,” Board Chairman Gary Titus said in a statement. “We are grateful for his ongoing commitment to execute a high quality clinical program, pursue a successful completion of the phase 3 trial while also advancing our Stem-to-T-cell program.” Shares closed down 4 cents, or less than 2 percent, to $2.11 on the New York Stock Exchange.
